Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

LGP Cannatrek Group has opened its post-merger era with positive operating cash flow, a healthy cash balance and a clearly defined cost-cutting program. The catch is that the June quarter does not provide a clean picture of the combined business.

The merger between Little Green Pharma and Cannatrek was completed on 1 June 2026. Under the required accounting treatment, the quarterly cash flow statement includes three months of Cannatrek cash flows but only one month from the former Little Green Pharma operations. That means the reported customer receipts and expenditure figures cannot sensibly be compared with earlier quarters, nor treated as a full-quarter run rate for the enlarged group.

The September quarter will therefore be the first proper financial test of the combined operation. Until then, investors are dealing with a financial photograph taken while half the family was still walking into frame.

Operating cash flow moves into positive territory

Net cash from operating activities was $1.85 million, supported by customer receipts of $22.92 million. Product manufacturing and operating costs totalled $7.76 million, staff costs were $5.57 million and administration and corporate costs came to $7.60 million.

The positive operating result is encouraging, especially in a sector where cash burn has often been treated as an occupational hazard. However, the cost base deserves close attention. Administration and corporate spending was almost as high as manufacturing and operating expenditure, while staff and corporate costs together consumed more than $13 million.

Some of that expenditure may reflect the transition to the merged structure, but the report does not break out merger-specific operating costs. Investors will be looking for corporate expenses to moderate as duplicated functions are removed and integration work progresses.

Management has identified $3 million of targeted synergies across manufacturing, cultivation, procurement and corporate functions. That target is meaningful relative to the current cash cost base, although the timing of the savings has not been quantified.

Cash position provides integration breathing room

Cash and cash equivalents finished the period at $20.59 million, up from $17.61 million at the start. The increase included $1.57 million of cash held by the former Little Green Pharma business when the merger became effective, so it was not entirely generated from trading.

The group also had $9.17 million of unused financing facilities, taking total available funding to almost $29.8 million. Financing facilities totalled $15.17 million, of which about $6 million had been drawn.

The company described debt as minimal at $5.9 million at the merger date. Borrowings are spread across property, equipment, inventory and working capital facilities, with interest rates varying according to lender and security arrangements.

This balance sheet gives management some room to integrate the businesses and invest in Europe without immediately returning to shareholders for capital. That matters because the group has begun funding expansion and efficiency initiatives in Denmark, while also building its presence in Germany and the United Kingdom.

One shadow remains the Therapeutic Goods Administration regulatory investigation. Management expects any penalty to be material but says it should remain within the limits of the contingent value share conversion mechanism. That may reduce the direct cash sting, but investors will still want clarity once the regulatory process is resolved.

Australia remains the engine room

Australia accounted for 84 per cent of group sales, with Europe and the United Kingdom contributing the remaining 16 per cent. The geographic weighting has shifted back towards Australia following the addition of Cannatrek, reflecting its strong domestic position.

Flower remained the dominant product category at 79 per cent of sales. Oils contributed 13 per cent, while edibles and vapes each accounted for 4 per cent. Flower is still very much the main course, but Cannatrek’s exposure to oils, edibles and vapes has reduced the combined portfolio’s dependence on it.

Cannatrek-branded products represented 46.9 per cent of sales and Little Green Pharma products contributed 29.6 per cent. Cornerfield accounted for 10.7 per cent and CherryCo 7.6 per cent, with the remaining brands making smaller contributions. Around three-quarters of sales came from the two core brand families, excluding European white-label activity.

Integration execution becomes the key measure

Management is running seven integration workstreams covering operational synergies, the Denmark facility, product optimisation, commercial strategy, technology systems, finance and quality systems.

Early priorities include combining commercial platforms, rationalising product portfolios and consolidating downstream operations. The domestic manufacturing assets and the Danish cultivation and production facility are being presented as complementary rather than duplicated infrastructure.

The strategic logic is straightforward: use Cannatrek’s Australian scale and product breadth alongside Little Green Pharma’s European production footprint and export relationships. The harder task is translating that logic into lower costs, better utilisation and sustainable cash generation.

The June quarter offers an encouraging starting point, but not yet a reliable trend. The next quarterly result should reveal whether positive operating cash flow survives a full three months of combined trading and whether the promised synergies are beginning to appear where they matter most - in the bank account.

Swift TV has entered FY27 with its flagship connected television platform commercially approved, a growing contracted device base and fresh capital to fund deployments. After several years devoted to product development, certification and testing, the investment case is now shifting towards execution.

Google certification and final Netflix approval remove two important technical hurdles. These approvals allow Swift TV to operate within Google’s certified enterprise ecosystem and formally integrate Netflix, strengthening the platform’s credentials across workforce accommodation, aged care and hospitality.

The commercial numbers are beginning to provide something more tangible than technical promise. Swift has sold 7,190 devices to 13 enterprise customers, with 3,736 devices deployed and live. That means 52 per cent of contracted rooms have been activated, leaving a sizeable installation task ahead.

Those customers collectively operate 171 sites, but only 24 sites have so far been contracted for Swift TV. The current 14 per cent site penetration suggests there may be considerable expansion potential within existing customer networks, although investors will want to see that opportunity converted into signed contracts and recurring revenue rather than remaining an attractive spreadsheet exercise.

Chevron provides heavyweight validation

The most meaningful customer development is Chevron’s decision to sign a five-year subscription agreement and order another 1,900 devices for Barrow Island and Wheatstone Offshore.

The additional order follows an initial deployment at Wheatstone Village. Once the expanded rollout is completed, Chevron is expected to have about 3,900 Swift TV devices across its accommodation facilities.

That progression matters because it demonstrates the platform can operate in large, remote and operationally demanding environments. A multinational resources customer moving from trial deployment to a broader five-year commitment is a more persuasive endorsement than a dozen pilot programs and a glossy brochure.

Aged care is also showing expansion within an existing enterprise account. Australia’s largest aged care provider has added three sites following an initial four-site rollout, lifting contracted subscriptions under its three-year agreement to more than 1,000 screens.

Hospitality, meanwhile, has emerged as a third commercial vertical. Daydream Island Resort has signed up for a 244-room deployment, while Seashells Hospitality Group will introduce the platform at two properties under a four-year subscription agreement. Seashells was already using Swift’s legacy services, giving the company an early example of how existing customers may be migrated to the new platform.

Revenue declines reveal the legacy gap

The operating progress sits alongside a less flattering set of unaudited FY26 numbers. Revenue is expected to fall to $13.9 million from $17.7 million, a decline of about 21 per cent.

Subscription revenue decreased to $12.2 million from $14.2 million, while project revenue roughly halved to $1.7 million from $3.5 million. The main culprit was the wind-down of services provided to Mineral Resources, which reduced FY26 subscription revenue by approximately $1.1 million.

The impact does not end there. Management expects the wind-down to remove another $2.1 million of revenue in FY27. That creates a clear hurdle for the new platform: fresh deployments must grow quickly enough to replace declining legacy sales before they can produce meaningful overall expansion.

Despite weaker revenue, unaudited EBITDA is expected to come in at about $800,000, compared with $1 million in FY25. Holding earnings relatively steady while revenue contracted points to cost efficiencies and potentially improved margins from the subscription model. However, EBITDA remains modest, and the company is not yet self-funding on a cash basis.

Cash improves, but capital remains precious

Customer receipts were $3.1 million for the June quarter, down from $4.3 million in March. Net operating cash outflow was $530,000.

Management notes that underlying operating cash performance improved by about $500,000 quarter-on-quarter after excluding the $1.5 million government grant and tax incentive received in the March period. Operating payments also fell to $3.63 million from $5.29 million, partly because project-related expenditure was lower.

Cash finished the quarter at $2.59 million, with another $235,000 held in unrestricted term deposits. The balance was supported by $1.84 million of equity proceeds during the quarter.

The company also completed a $2.33 million placement and debt conversion, comprising $1.9 million from investors and $430,000 of debt converted into equity. This improves near-term liquidity, but shareholders must weigh that benefit against dilution and the continuing debt burden.

Swift’s $5.86 million secured facility is fully drawn, carries interest of 10.25 per cent and matures in March 2027. Finance costs totalled $222,000 during the June quarter. The reported cash position equates to an estimated five quarters of funding at the latest operating cash burn, although upcoming inventory purchases and deployment costs could make the cash trajectory uneven.

FY27 becomes the execution test

Swift plans to order another 5,000 devices while deploying Chevron, aged care and hospitality contracts. Its workforce accommodation sales pipeline now exceeds 50,000 rooms, supported by reseller partners, while discussions continue with prospective US hospitality distributors following the HITEC conference.

The opportunity is increasingly visible. So are the risks.

Investors now have several useful measures to watch: deployed devices, contracted sites, subscription revenue growth, operating cash flow and progress replacing the Mineral Resources revenue shortfall. The technology has cleared its major certification gates. FY27 will show whether Swift can turn those approvals and customer endorsements into a scalable, cash-generating business.

Argent BioPharma has broadened the global licensing framework for CannEpil to include veterinary healthcare, giving the cannabinoid therapy a second commercial pathway alongside its existing human neurological applications.

The revised agreement preserves Argent’s 15% perpetual royalty on future human therapeutic sales while introducing a separate 10% perpetual royalty on veterinary applications. For investors, the significance is not simply that CannEpil can now be sold into another market. The structure potentially allows Argent to participate in animal health revenues without surrendering ownership of the underlying intellectual property or taking primary responsibility for the veterinary development program.

Argent will retain all existing and future CannEpil intellectual property, manufacturing know-how and regulatory assets. It also expects to continue manufacturing the product through its EU-GMP network, creating the possibility of earning both royalty income and manufacturing revenue if commercialisation is achieved.

That is a capital-efficient model on paper: let external partners fund and execute much of the development work while Argent keeps a slice of future sales and control of the crown jewels.

The US regulatory route takes shape

Splash Beverage Group, Argent’s licensing partner, has advised that it intends to collaborate with Lupvindol UK Limited on the veterinary program. The proposed partners plan to pursue development through the US Food and Drug Administration’s Center for Veterinary Medicine.

The expected pathway includes an Investigational New Animal Drug application and the FDA’s Conditional Approval process. Conditional approval can provide a route to market while further effectiveness data are collected, although approval is not guaranteed and the regulatory process can still be lengthy, costly and technically demanding.

Importantly, Splash remains responsible for its obligations under the exclusive licensing agreement. Argent has consented to limited use of its intellectual property for the veterinary program, but it has not transferred ownership.

The wording deserves attention. Splash “intends” to enter into a development and collaboration agreement with Lupvindol. That suggests the veterinary strategy has direction, but the collaboration itself should not yet be treated as a completed development partnership unless and until definitive arrangements are executed.

A broader market, but no near-term numbers

The animal health expansion gives CannEpil access to a potentially meaningful new commercial category, particularly if the therapy can be developed for neurological conditions in companion animals. However, the company has not disclosed the specific veterinary indication, expected development costs, regulatory milestones, commercial launch timing or projected revenue.

There is also no disclosed upfront payment linked to the amendment. The immediate value is therefore strategic rather than financial: Argent has widened the addressable market and created another potential recurring revenue stream, but investors do not yet have enough information to model its contribution.

The 10% veterinary royalty is lower than the 15% human therapeutic royalty. That difference reflects the involvement of a specialist veterinary development partner and the need for a separate regulatory and commercial program. Whether the lower rate proves attractive will depend on eventual sales volumes, development progress and how much manufacturing income Argent can retain.

CannEpil already has a commercial foundation

CannEpil is a pharmaceutical-grade cannabinoid oral solution formulated at a 20:1 ratio of CBD to THC. It was developed for drug-resistant epilepsy, a condition affecting roughly one-third of epilepsy patients worldwide.

The product has regulatory or commercial access pathways in Ireland, the United Kingdom, Germany and Australia, supported by real-world clinical evidence, peer-reviewed publications and EU-GMP manufacturing infrastructure. Argent also points to an active US investigational new drug program for human use.

CannEpil has achieved full reimbursement in Ireland under the Medicinal Cannabis Access Programme and recently completed its largest commercial shipment, with 1,000 units delivered to the Irish market. That does not yet establish a large revenue base, but it means the veterinary opportunity is being built around an existing pharmaceutical asset rather than a laboratory-stage concept.

What investors should watch next

Chairman Roby Zomer said the amendment preserved Argent’s participation across both human and animal health applications while maintaining ownership of the intellectual property and manufacturing capabilities.

The next meaningful developments will be execution of the Lupvindol collaboration, clarification of the target animal indication, acceptance of the regulatory strategy by the FDA, commencement of development work and disclosure of commercial milestones.

The veterinary expansion strengthens the optionality around CannEpil and fits Argent’s stated strategy of combining owned intellectual property with licensing, manufacturing and recurring royalties. But the investment case will ultimately depend on execution. A perpetual royalty is valuable only when the underlying product reaches the market and generates sustainable sales.

Pointerra’s June quarter supplied something technology investors have been waiting to see for some time: commercial momentum translating into a substantially better cash result.

Customer receipts reached $2.15 million, up 33 per cent from $1.61 million in the previous corresponding quarter. More importantly, second-half receipts climbed 84 per cent to $4.32 million. The quarterly operating cash outflow narrowed to just $93,000, compared with a $1.01 million outflow a year earlier and $300,000 in the March quarter.

For the full financial year, operating cash outflow was $288,000, a 67 per cent improvement from $880,000 in FY25. Annual customer receipts totalled $8.91 million. That is close enough to breakeven for management’s claim of positive operating cashflow in FY27 to be plausible, although one swallow does not make a cash-generative SaaS business.

Pointerra finished June with $1.41 million in cash and no financing facilities. The headline balance remains modest, but the company had $2.42 million of receivables at quarter-end, including $1 million collected during July. Contracted work and renewals provide further near-term support.

The statutory cash-runway calculation came in at 15.19 quarters, but investors should treat that figure as mathematical rather than prophetic. It divides the cash balance by the unusually small June-quarter outflow. A few delayed customer payments or additional hiring decisions could move it sharply in either direction.

Utilities become the commercial engine room

The strongest evidence of Pointerra’s enterprise credentials continues to come from electricity utilities, where the cost of vegetation encroachment, damaged infrastructure or delayed inspection can be far greater than the software bill.

Western Power awarded the company a three-year contract covering an initial 50 transmission substations, with the platform capable of expanding across approximately 155 sites. In the United States, Pacific Gas & Electric awarded contracts worth US$490,000, or about $700,000, covering management of its historic geospatial survey catalogue and analytics for emergency-management change reporting.

The US Department of Energy-backed GRACI project with Georgia Power also continued progressing towards data-driven vegetation-spending prioritisation. The engagement is worth US$2 million and is strategically important because it could provide an independent government-backed reference case for the technology.

A potentially larger prize is the engagement supporting Baltimore Gas and Electric’s vegetation-management program. The initial proof-of-value covers 185 miles, with an automatic extension to the remaining 9,815 miles following successful completion. Pointerra says its platform can compress a workflow previously measured in months into less than three days. That is the sort of productivity claim that will attract attention - provided the proof-of-value converts as planned.

Shortly after quarter-end, Avista entered a three-year enterprise subscription covering the Core platform, Utility Explorer and contracted analytics consumption. Management has identified the Western Power, Pacific Gas & Electric, Origin Energy and Avista deployments as having further recurring-revenue upside as platform usage expands.

Origin opens another pipeline

Pointerra also secured a multi-year agreement with Origin Energy covering automated threat detection, compliance reporting and change analysis across about 750 kilometres of Queensland gas pipelines.

The initial term runs for three years, with an option for another two, providing up to five years of revenue visibility. Operations are scheduled to begin in the September quarter, using drone-acquired lidar and imagery supplied by Carbonix.

The arrangement neatly demonstrates Pointerra’s intended role in the digital-twin ecosystem. A capture partner gathers the data, Pointerra processes and manages it, and the asset owner consumes the analytics. When that chain works properly, the platform becomes less like a one-off software tool and more like embedded infrastructure.

Mining activity also included new or renewed work with BHP, Anglo American, Yancoal and Rio Tinto Aluminium, while California Resources Corporation signed a three-year subscription. Agnico Eagle committed to a proof-of-value for underground mining analytics, although a separate Tier 1 hazard-management deployment remains paused while the customer restructures.

Product investment shifts towards scalable consumption

Pointerra continued enhancing its Core platform, including automated point-cloud quality reporting, improved volume measurement and processing-unit-based analytics pricing. The last item matters commercially because transparent usage pricing could allow analytics revenue to grow with customer consumption rather than remain trapped inside fixed subscriptions.

The company is also reducing reliance on third-party technology across imagery delivery and 3D modelling. Management expects these changes to improve repeatability, reduce processing complexity and support stronger margins as project volumes grow.

The quarter marks genuine progress rather than mission accomplished. Cash reserves remain limited, several opportunities still depend on proofs-of-value or customer-controlled rollouts, and no consolidated ARR figure was disclosed. But with receipts accelerating, enterprise renewals broadening and major utilities moving from experimentation to multi-year deployment, Pointerra is beginning to look less like a promising digital-twin laboratory and more like a commercial software business.

Adisyn has strengthened its United States intellectual property position after the US Patent and Trademark Office allowed a second patent application covering graphene-coated products intended for next-generation semiconductor applications.

The latest allowance relates to graphene-coated three-dimensional surfaces, including semiconductor interconnects with defined physical and purity characteristics. It complements the company’s earlier US patent allowance, disclosed in May 2026, which covered a method for applying tethered graphene coatings to metallic surfaces as well as the resulting products and devices.

For investors, the important distinction is that the new claims are focused on the characteristics of the finished product rather than being restricted to Adisyn’s particular manufacturing process.

That could make the protection harder to sidestep.

A competing manufacturer may potentially use different precursors, equipment or production techniques, but could still fall within the patent claims if its finished graphene-coated surface displays the protected specifications.

Patents are never an automatic ticket to commercial success, but product-based claims can provide a broader defensive perimeter than process claims alone. Adisyn is effectively seeking protection for both the recipe and selected characteristics of the meal.

What the patent claims cover

The allowed claims apply to uniform and conformal graphene coatings deposited over complex three-dimensional geometries.

The protected products may also include copper interconnects with a median grain size below 0.9 microns, fewer shorts and voids following exposure to temperatures of at least 400 degrees Celsius, or metal that is substantially free of conventional diffusion barrier coating materials.

The claims also cover graphene coatings without nitrogen doping, iron chloride residuals or remaining metal catalyst nanoparticles.

These details matter because semiconductor interconnects are the microscopic wiring structures that carry electrical signals within a chip. As processors become smaller and more densely packed, copper interconnects encounter rising electrical resistance, heat and reliability challenges.

Adisyn is developing a low-temperature atomic layer deposition process intended to grow graphene directly on semiconductor wafers. The company believes graphene could improve the performance of copper interconnects while reducing or removing the need for conventional diffusion barriers.

Those barriers help prevent copper from migrating into surrounding materials, but they also occupy valuable space. At advanced semiconductor dimensions, every sliver of room counts.

Managing director Arye Kohavi said copper grain size and reductions in shorts and voids could affect electrical resistivity and thermal performance. He also noted that removing conventional diffusion barrier materials could create additional space as processors continue to scale.

A layered defence rather than a single patent bet

Adisyn’s intellectual property strategy extends beyond registered patents. The company is retaining some technical knowledge as trade secrets, including proprietary processes, operational expertise and accumulated manufacturing know-how.

That approach is common in emerging technology fields. A patent provides enforceable rights in exchange for public disclosure, while trade secrets protect information that may be more valuable when kept behind closed laboratory doors.

The combination may become increasingly important as Adisyn moves from research towards process scale-up and discussions with potential commercial partners.

The May allowance protected a graphene coating method and its outputs. The latest allowance adds claims centred on the physical properties of the coated products. Together, they provide overlapping protection across how the technology is produced and what the resulting product looks like.

The company is also assessing additional patent filings in other jurisdictions, suggesting its intellectual property strategy remains a work in progress rather than a completed portfolio.

Commercial proof remains the next hurdle

The allowance is strategically useful, but investors should distinguish intellectual property progress from commercial validation.

Adisyn has not disclosed a semiconductor manufacturing contract, licensing agreement or revenue forecast arising from the patent. Nor has it provided economic details covering production costs, manufacturing yields or the capital required to scale the technology.

Those are critical issues in semiconductor materials development, where an impressive laboratory result must still survive rigorous qualification, integration and high-volume manufacturing requirements.

The company said it is progressing engagement with potential partners and customers across its semiconductor interconnect program and its separate radar signature reduction business.

That second application involves advanced composite materials intended to reduce radar signatures in unmanned aerial vehicles and defence platforms. While both programs draw on Adisyn’s graphene expertise, they address very different markets and commercial pathways.

The latest patent allowance therefore improves the company’s strategic position without removing the execution risk. The investment case will increasingly depend on whether Adisyn can convert its expanding intellectual property portfolio into industry partnerships, funded development programs or commercial agreements.

For now, the company has added another layer to its graphene armour. The harder task is proving there is a paying customer waiting on the other side.